共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Embolic protection device, the next advancement in TAVR?显示文摘The approval of commercial application transcatheter aortic valve replacement(TAVR)by the FDA in 2011 has revolutionized the management of high-risk surgical patients with severe aortic stenosis(AS).With TAVR being expanded to intermediate surgical risk patients in 2016,the number of patients undergoing TAVR has been increasing rapidly.In fact,since the very first human TAVR procedure in 2002,more than 300,000 TAVRs have been performed worldwide.[1,2]The technological advancements in the TAVR since its early days of clinical adaptation has made this procedure a routine practice in many institutions worldwide.However,one of the most feared complications,ischemic stroke,remains a major concern for clinicians and patients despite all the advancements in the procedure. | David Li Nicole Shirakawa Hong Liu | 2020 | Journal of Geriatric Cardiology2020，17，3： | 0 |
| 2 | Is a designated arterial catheter indicated in transcatheter aortic valve replacement procedure?显示文摘Aortic stenosis(AS)is the most common valvular disorder frequently affecting patients as they get older,and resulting in life-altering symptoms such as dyspnea,angina,pre-syncope,and syncope,which are often made worse with exertion.Often,AS is caused by age-related calcification of the valve;in addition,its pathogenetic mechanism also involves the fact that bicuspid aortic valves tend to narrow rapidly compared to other three-leaflet valve.As the aging population continues to grow,an increasing number of patients are seeking treatment for AS,which makes therapies for AS continuing to evolve and improve.Initially,surgical aortic valve replacement(SAVR),requiring a median sternotomy and an extended post-operative intensive care unit stay,was the predominant therapy for patients with AS. | Pooja Patel Lillian Jundi David Li Hong Liu | 2022 | The Journal of Biomedical Research2022，36，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员